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A large body of data from epidemiologic, clinical trial, animal, and in vitro studies demonstrate adverse consequences of
industrially synthesized trans fatty acids (TFAs) on the risk of coronary heart disease (CHD). A growing database of more recent
researchfromvirtuallyallexperimentalmodelsdemonstratesevidenceofdetrimentalconsequencesofTFAsontheriskofdiabetes.
Evidence is accumulating about the physiological and cellular mechanisms of action that account for the many adverse effects
TFAshaveonCHDanddiabetes.Inarelativelyshortperiodoftime(i.e.,fromaroundtheearly1990stothepresenttime,oralmost
20 years), we have gained a good understanding of the health effects of TFAs from epidemiologic studies, clinical trials/studies,
animal research, and in vitro experiments that collectively justify current dietary recommendations made by numerous government
agencies and health organizations to consume a diet with as little TFAs as possible. Public policy actions have been implemented
and TFAs appear on the Nutrition Facts Panel. Some cities have also mandated zero TFAs in restaurants. The research on TFAs
is a good example of how an evidence base has been built and translated into public policy that targets improved health. It is
impressive that the TFA research has been coupled to public policy actions to decrease TFAs in the food supply so quickly.
A seminal paper published by Mensink and Katan (1990) reported that a diet with 10% of energy from TFAs versus a diet
with 10% of energy from oleic acid signiﬁcantly (P<0.001) increased LDL cholesterol (LDL-C) (14 mg/dL) and signiﬁcantly
lowered (P< 0.001) HDL cholesterol (HDL-C) (7 mg/dL). Saturated fat (10% of energy) also increased LDL-C (18 mg/dL),
but had no effect on HDL-C compared with oleic acid. The authors concluded that the effect of TFAs on the serum lipoprotein
proﬁle is at least as unfavorable as that of the cholesterol-raising saturated fatty acids (SFAs) because of their similar LDL-C
raising effects. Moreover, TFAs may be more detrimental because they also lower HDL-C versus SFAs. Soon after, Willett and
colleagues (1993) published the results from the Nurses’ Health Study of 85,095 women without diagnosed CHD, stroke, diabetes,
or hypercholesterolemia at the start of the study, and reported that the intake of TFA isomers was related to the risk of CHD
after 8 years of follow-up. Using the Willett food frequency questionnaire, the authors reported that TFAs increased relative risk
(highest versus lowest quintile was 1.50 [95% conﬁdence interval: 1.12–2.00], P for trend = 0.001). The authors concluded that
the consumption of partially hydrogenated vegetable oils may contribute to occurrence of CHD.
In an early review evaluating the scientiﬁc evidence on TFAs and CHD (Allison et al., 1995), data supporting a relation
between TFA intake and CHD risk were considered equivocal on the basis of results reported from observational studies that had
methodological limitations, and animal studies that showed no differences in LDL-C and atherosclerosis incidence in response
to diets high in TFAs. The authors called for additional research to resolve questions about the independent effects of TFAs on
plasma lipoproteins and their mechanisms of action. In a position paper on TFAs published by the American Society of Clinical
Nutrition (ASCN)/American Institute of Nutrition (AIN) Task Force on Trans Fatty Acids (1996), the authors noted, based on
the state of the science to date, that it cannot be concluded that the intake of TFAs is a risk factor for CHD. The position paper
noted that there were few rigorous studies that addressed the biomedical effects of TFAs and possible mechanisms relevant to
human health and disease. Before making any new dietary recommendations or changes in nutrition policy concerning TFAs, the
position paper concluded that data were needed, comparable to that available for SFAs, about the intake of TFAs, their biological
effects and associated mechanisms of action, and their relation to disease. Based on the current database available at the time of
its publication, the ASCN/AIN position paper on TFAs concluded that it was premature to make new dietary recommendations
for the population at large or to change nutrition policy with respect to TFA labeling. The “early” consensus was that the “debate”
about TFAs should not detract from the role that SFAs played in CHD risk.
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Over the next decade, additional epidemiologic studies were published that showed a consistent adverse association of TFAs
with increased CHD risk (reviewed by Mozaffarian et al., 2006). In addition, well-controlled, clinical studies were conducted that
showed a dose-response relationship between dietary TFAs and LDL-C (Judd et al., 2002; Lichtenstein et al., 1999). Collectively,
the clinical studies demonstrated a dose-response relationship between TFA intake and TC/HDL-C (reviewed by Ascherio et al.,
1999). Meta-analyses evaluated the effects of substituting TFAs for carbohydrate calories and demonstrated an LDL-C raising
effectthatwassimilartoSFAs;however,unlikeSFAs,TFAsdidnotraiseHDL-C(Mensinketal.,2003),resultingintheconclusion
that TFAs lower HDL-C compared to SFAs and consequently increase the LDL-C/HDL-C ratio, which is a strong independent
risk factor for CVD.
In a relatively short period of time, there has been an impressive evolvement of the evidence base demonstrating an adverse
relationship between TFA intake and CHD risk. The epidemiologic studies were instrumental in establishing the rationale for
conducting well-controlled clinical studies that deﬁnitively demonstrated the role that TFA intake played in CHD risk. The
proliferation of the evidence base was key for the current actions/policies that have been implemented to decrease TFAs in the food
supply. The emerging data or TFA intake and diabetes incidence (Riserus et al., 2009) insulin resistance and adiposity (Teegala
et al., 2009) could reinforce the importance of decreasing TFAs in the diet. It will be interesting to see how this story will unfold.
Other emerging questions about TFAs to resolve include determining the effects of animal TFAs versus industrially synthesized
TFAs (Willett and Mozaffarian, 2008) and the biological effects of the individual industrially synthesized TFA (Lemaitre et al.,
2006). Nonetheless, it is beyond debate that removing industrially produced TFAs from the diet will decrease risk of chronic
disease(s) such as CHD and, possibly, diabetes.
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